Study of Medtronic Hugo™ robotic-assisted surgery system in hernia repair meets safety and effectiveness endpoints
(NYSE:MDT) First-ever investigational device exemption clinical study for robotic-assisted hernia repair in the U.S. presented at the American Hernia Society annual meeting GALWAY, Ireland and NASHVILLE, Tenn., Sept. 4, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced results from the...
Related Questions
How will the positive study results affect Medtronic's upcoming earnings guidance and revenue forecasts for its surgical portfolio?
What is the timeline for FDA approval and commercial launch of the Hugo system for hernia repair, and how might that impact the stock in the near term?
How does the performance and cost structure of Hugo compare to competing robotic platforms, and could this shift market share?